Validation of sputum supernatant biomarker assays in stable and exacerbating COPD subjects Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
High sputum ECP levels detect functional impairment in asthma better than sputum eosinophils Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010
The success of obtaining the induced sputum of patients with COPD Source: International Congress 2019 – Nursing care across the spectrum of respiratory illnesses Year: 2019
Increased sputum IL-1β and IL-5 gene expression in exacerbations of COPD demonstrated with real-time PCR Source: Eur Respir J 2004; 24: Suppl. 48, 319s Year: 2004
Usefulness of a panel of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases Year: 2011
Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD Source: Eur Respir J, 55 (5) 1902412; 10.1183/13993003.02412-2019 Year: 2020
Evaluation of FeNo measurement as an alternative to sputum eosinophils in a severe asthma population Source: International Congress 2017 – Biomarker-based asthma control Year: 2017
Sputum induction in asthmatic children: safety in children and feasibility of new methods of monitoring inflammation in sputum samples Source: Eur Respir J 2006; 28: Suppl. 50, 259s Year: 2006
Il-6 levels in sera and induced sputum of COPD patients during exacerbations and stable period Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005
Repeatability of inflammatory analysis in induced sputum samples in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 469s Year: 2004
Increased levels of hyaluronan in induced sputum from COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 436s Year: 2003
Increased levels of osteopontin in sputum supernatant in patients with COPD Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers Year: 2012
Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline Source: International Congress 2017 – Infection and exacerbation science Year: 2017
Role of sputum eosinophil levels in the assessment of asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004
Our experience of procalcitonin assay in identifying bacterial COPD exacerbations Source: Annual Congress 2011 - COPD exacerbation Year: 2011
Inflammatory markers in sputum of patients with cough variant asthma Source: Eur Respir J 2002; 20: Suppl. 38, 584s Year: 2002
Sputum VEGF level increases with treatment of COPD acute exacerbation Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation Year: 2012
Evaluation of novel sputum processing methods and sensitive detection techniques in allergic asthmatics Source: Annual Congress 2009 - What is new in the regulation and monitoring of airway function? Year: 2009
Effectiveness of a panel of sputum markers in smokers with and without COPD to detect pulmonary progression towards functional impairment Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020
The use of sputum differential cell counts and soluble phase measurements to assess airway inflammation in children with asthma exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 142s Year: 2002